EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability

MLA

Michels, S., et al. EATON: An Open-Label, Multicenter, Phase I Dose-Escalation Trial of Nazartinib (EGF816) and Trametinib in Patients with EGFR-Mutant Non-Small Cell Lung Cancer - Preliminary Data on Safety and Tolerability. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....be0f3e41924e65d9109c2dabd6ab782d&authtype=sso&custid=ns315887.

APA

Michels, S., Nogova, L., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Felip, E., Rodriguez-Abreu, D., Rosell, R., Abdulla, D., Fischer, R., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Scheffler, M., Suptitz, J., Fassunke, J., Merkelbach-Bruse, S., … Wolf, J. (2019). EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability.

Chicago

Michels, S, L Nogova, B Deschler-Baier, M Sebastian, M Schuler, M Wermke, E Felip, et al. 2019. “EATON: An Open-Label, Multicenter, Phase I Dose-Escalation Trial of Nazartinib (EGF816) and Trametinib in Patients with EGFR-Mutant Non-Small Cell Lung Cancer - Preliminary Data on Safety and Tolerability,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....be0f3e41924e65d9109c2dabd6ab782d&authtype=sso&custid=ns315887.